Pharmaceuticals, Biotechnology and Life Sciences
GeGant® for the U.S. market will be produced and distributed by ITM’s long-term partner RadioMedix GARCHING, Germany & HOUSTON–(BUSINESS WIRE)–ITM…
German independent research institute Biomed X announces has completed its first joint research project with Boehringer Ingelheim in the fields of neuroscience. The results of the project are transferred to Boehringer Ingelheim for further development.
Piramal Pharma Solutions has said it plans to expand its facility in Riverview, Michigan, for which it will invest approximately $32 Million to add capacity and new capabilities in potent and non-potent API development and manufacturing.
Immunicum AB has received Fast Track Designation (FTD) from the U.S. Food and Drug Administration (FDA) for the Company’s lead…
Relief Therapeutics and NeuroRx have met the 165 patient enrollment target agreed with the U.S. Food and Drug Administration (FDA) in the ongoing phase 2b/3 trial of RLF-100 (aviptadil) for treating Respiratory Failure in patients with Critical COVID-19.
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking approval of amivantamab for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations whose disease has progressed on or after platinum-based chemotherapy.
COVID-19 is the medical emergency of the century. Since the pandemic began in December 2019, the new coronavirus, termed SARS-CoV-2 has caused havoc in almost every country, with more than 40 million proven cases of the disease termed COVID-19, including one million deaths.
The UK has approved Pfizer’s COVID-19 vaccine on Wednesday, becoming the first country in the world to do so, going ahead of the United States and the EU countries, who expect to bring the decisions on authorization in December.
Regeneron Pharmaceuticals and Sanofi today announced that the European Commission (EC) has extended the marketing authorization for Dupixent (dupilumab) in the European Union (EU) to include children 6 to 11 years of age with severe atopic dermatitis who are candidates for systemic therapy. Dupixent is the only systemic medicine approved in the EU to treat these patients.
The Swansea University Medical School plans a clinical trial with Iota-/kappa-carrageenan nasal spray as a COVID-19 Prophylaxis for Healthcare Professionals (ICE-COVID), to test Marinomed Carragelose nasal and throat spray in reducing the rate, severity, and duration of COVID-19 infections.